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Abstract
Background: After resection surgery for Crohn’s disease, recurrence of endoscopic lesions at the 
site of the anastomosis or in the neoterminal ileum is graded according to the Rutgeerts score 
(RS). The goal of this study was to test the interobserver variability for RS.
Methods: Thirteen trained endoscopists evaluated the RS on 39 videotapes of patients who had 
undergone resection for Crohn’s disease with an ileocolonic anastomosis 6 months earlier. Videotapes 
were randomly assigned to endoscopists through a balanced incomplete block design. Each videotape 
was scored independently by four endoscopists, and each endoscopist evaluated 12 videotapes, 
making a total of 156 videotape assessments. Reproducibility levels of the RS were assessed through 
unweighted kappa estimates among multiple raters. The proportion of inappropriate therapeutic 
initiation was estimated by randomly selecting one endoscopist for each videorecording, assuming 
that the majority of endoscopists correctly classified endoscopic recurrence.








Results: The kappa estimates were 0.43 (95% confidence interval: 0.33–0.52) for the RS on a 5-grade 
scale, 0.47 (0.28–0.66) for RS < i2 vs. ≥ i2, and 0.64 (0.42–0.85) for RS ≤ i2 vs. > i2. The percentages 
of inappropriate therapeutic initiation were 12.8% (3.8–21.9) when initiation was triggered by a RS 
≥ i2 and 8.3% (1.1–15.6) when initiation was triggered by a RS > i2 (p = 0.41).
Conclusion: The reproducibility of the RS was moderate, especially when differentiating <i2 from 
≥i2, which may lead to incorrect therapeutic decisions in >10% of patients.
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Introduction
Despite recent advances in medical management, many patients with 
Crohn’s disease (CD) still require intestinal surgery throughout their 
lives.1 Surgery is not a cure, and postoperative recurrence is common 
in patients with CD.2 Ileocolonoscopy is considered to be the gold 
standard in the diagnosis and monitoring of CD endoscopic recur-
rence after surgery, both in clinical trials and clinical practice.3–11 
Endoscopic activity at the anastomotic site and in the neoterminal 
ileum after ileocolonic resection is graded using a scoring system 
developed by Rutgeerts et al.12 Endoscopic recurrence is commonly 
defined as a score of i2–i4 (i.e. ≥i2) and used to initiate a new ther-
apy in an attempt to prevent clinical recurrence in the following 
months. However, since its description in 1990, the properties of the 
Rutgeerts score (RS) have been poorly studied.
The aim of the present interobserver variation study was to assess 
the reproducibility level of the RS and to assess how this could affect 
therapeutic decision-making after surgery.
Patients and methods
The present study was an interobserver variation study performed 
on videorecorded ileocolonoscopies of patients recruited and fol-
lowed-up in either of two clinical trials conducted in 11 French 
centres from the Groupe d’Etude Thérapeutique des Affections 
Inflammatoires du tube Digestif (GETAID). These two controlled 
trials (GETAID 2001-1 and GETAID 2001–2) evaluated CD post-
operative recurrence in patients receiving 5-aminosalicylate acids 
(5-ASA), azathioprine (unpublished data), Lactobacillus johnsonii 
La1, or placebo, respectively.11 Inclusion criteria for the present 
study were the following: adults with CD diagnosed according to 
the usual criteria, bowel resection (right ileocolectomy or colectomy 
with ileocolic or ileorectal anastomosis) removing all macroscopic 
intestinal lesions, anastomosis accessible by standard colonoscopy, 
and complete endoscopic evaluation 6  months after surgery and 
with videorecording. Patients with colo-colic or colorectal anasto-
mosis and patients whose ileocolonoscopy was not recorded were 
excluded. All subjects gave written informed consent for these stud-
ies, which were approved by the Ethics Committee.
Endoscopists involved in the interobserver variation study were 
operators trained in inflammatory bowel disease and using RS in 
current practice. Allocation of the videos to be assessed by each of 
the 13 endoscopists was performed through a balanced incomplete 
block randomization so that each of the 39 videos was evaluated 
independently by four endoscopists blinded to the patient’s charac-
teristics. Each endoscopist evaluated 12 videos, and 156 videotape 
assessments were performed (detailed data are provided in the sup-
plementary material table). Endoscopists evaluated the RS using its 
definition and five-grade scale (i0 to i4) (Table 1).12
The reproducibility levels of the RS were assessed through 
unweighted kappa estimates among multiple raters.13 Agreement 
was determined for the RS relative to the cut-off of ≥i2 and relative 
to the cut-off of >i2 being used to define severe endoscopic recur-
rence). The agreement was considered as ‘moderate’ for kappa val-
ues of 0.41–0.60, ‘substantial’ for kappa values of 0.61–0.80, and 
almost perfect for kappa values above 0.80.14
We first assumed that a score of ≥i2 would trigger initiation of 
medical therapy. This cut-off value has been used as the main end 
point in most clinical trials studying the prevention of postoperative 
recurrence in CD.3,6–11 When using this assumption, the four assessors 
may disagree on the need for medical therapy because they disagree 
on RS relative to i2; for instance, one may score i1 and the three 
others i2. To estimate the proportion of inappropriate therapeutic 
initiations, we assumed that when three assessors agreed on the RS 
relative to the cut-off used to initiate intervention (i.e. three evalua-
tions under the cut-off or, alternatively, three evaluations at or above 
the cut-off), their evaluation led to an appropriate therapeutic initia-
tion. Thus, the evaluation of the last assessor, the one who disagreed 
with them, would have led to an inappropriate therapeutic initiation. 
Consequently, if we selected at random one of the four assessors 
when three assessors agreed and the fourth differed, 25% of the selec-
tions would have led to an inappropriate therapeutic initiation. When 
two assessors made an evaluation indicating therapeutic initiation, 
whereas the other two made an evaluation indicating the opposite 
decision, any assessor had a 50% chance of recommending appropri-
ate therapeutic initiation according to the criteria. Consequently, if 
we selected at random one of the four assessors when two assessors 
agreed on therapeutic initiation and two on no therapeutic initiation, 
half the selections would have led to an inappropriate therapeutic ini-
tiation. In all other situations, all assessors agreed, and if we selected 
at random one assessor, none would have indicated an inappropriate 
therapeutic initiation. According to the number of cases in which each 
situation was observed, it was possible to calculate, through binomial 
distribution, the probability that an evaluation would have led to an 
inappropriate therapeutic initiation when selecting at random one 
endoscopist out of the four who assessed each of the 39 videorecord-
ings (see the supplementary appendix for detailed calculations). 
Table 1: The Rutgeerts score of ileal and anastomotic lesions.12
i0: no lesion
i1: ≤5 aphthous lesions
i2: >5 aphthous lesions with normal mucosa between the lesions, or skip areas of larger lesions or lesions confined to the ileocolonic anastomosis
i3: diffuse aphthous ileitis with diffusely inflamed mucosa
i4: diffuse inflammation with larger ulcers, nodules, and/or narrowing
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The same type of calculation was repeated, but assuming that a score 
of >i2 was used to initiate a new treatment.
These calculations allowed us to estimate the difference in the 
proportions of inappropriate therapeutic initiations (with the 95% 
confidence interval) when using ≥i2 versus ≥i3 as the cut-off RS, tak-
ing into account the pairing of these data.
All results (kappa values and the probabilities of an evaluation 
leading to an appropriate therapeutic initiation) are presented as 
estimate ± standard error (SE) (95% confidence interval). Analyses 
were performed with the software SPSS®.
Results
The clinical characteristics of the 39 patients are displayed in Table 2.
The unweighted kappa ± SE estimate for the RS was 0.43 ± 0.05 
(0.33–0.52) on a 5-grade scale, showing ‘moderate’ agreement. The 
kappa estimate ± SE was 0.47 ± 0.10 (0.28–0.65) for the RS rela-
tive to the cut-off value of i2 or more (‘moderate’ agreement), and 
0.64 ± 0.11 (0.42–0.85) for the RS relative to the cut-off value of >i2 
(‘substantial’ agreement).
When initiating treatment for a RS of ≥i2, assuming that the 
majority of assessors made the correct evaluation for appropriate 
therapeutic initiation, the estimate of the number of evaluations 
leading to an inappropriate therapeutic initiation was 5.00, with a 
variance of 3.25, leading to an estimate of the probability of inappro-
priate therapeutic initiation of 12.8% (3.8–21.9), which corresponds 
to one in eight patients. When deciding on treatment for a RS of 
>i2, the estimated number of evaluations leading to an inappropriate 
therapeutic initiation was 3.25, with a variance of 2.06, leading to 
an estimate of the probability of inappropriate therapeutic initiation 
of 8.3% (1.1–15.6). The estimated difference between the number of 
evaluations leading to an inappropriate therapeutic initiation accord-
ing to the cut-off of ≥i2 versus >i2 was 1.75, with a variance of 4.44, 
taking into account the pairing of these two numbers evaluated on 
the same videotapes, leading to a difference in the probability of inap-
propriate therapeutic initiation of 4.5% (‒6.1–15.1) (p = 0.41).
Discussion
To our knowledge, the present study is one of the first that has for-
mally assessed the interobserver variation for RS. In addition, it 
attempted to derive the consequences of the variation in RS evalua-
tion in terms of a patient’s management. The main result is that the 
reproducibility of RS evaluation on a 5-grade scale was moderate, as 
was its evaluation relative to a cut-off of < i2 versus a cut-off > or 
= i2 indicating therapeutic initiation. As a consequence of the latter 
variation, we estimated that one therapeutic decision out of eight 
could be inappropriate.
Only three other studies have estimated the reproducibility level 
of the RS score on a 5-grade scale. In the Daperno et al. study, 10 
postoperative CD colonoscopies were evaluated by 14 experts, lead-
ing to 140 assessments.15 In the Kennedy et al. study, 43 colonosco-
pies were evaluated by five experts, leading to 215 assessments.16 In 
the Gesce et al. study, 25 colonoscopies were evaluated three times 
by four experts, leading to 100 independent assessments.17 In our 
study, 13 experts were involved in the evaluation of 39 colonosco-
pies, leading to 156 assessments. As a consequence of the assign-
ment of assessments through an incomplete balanced block design, 
the endoscopist and colonoscopy samplings were rather large in our 
study, with the total number of assessments being similar to that in 
the three previous studies.
The kappa estimates for RS evaluation on a 5-grade scale were 
quite similar in three studies: 0.53 in the Daperno et  al. study,15 
0.50 in the Kennedy et al. study,16 and 0.43 in the present study, 
confirming a moderate agreement. In the Gesce et  al. study, the 
intraclass  correlation coefficient (ICC) was 0.72,17 a level quite 
similar to those obtained with the same statistics in the Kennedy 
et al. study (0.82)16 and in the present study (0.76). Nevertheless, 
when using ICC instead of unweighted kappa to estimate the agree-
ment level of the RS on a 5-grade scale, much higher levels of agree-
ment were systematically obtained, corresponding to an almost 
perfect agreement when applying the same rules to the ICC as those 
used for kappa. This apparent contradiction is the consequence of 
the equivalence between ICC and weighted kappa for ordinal data 
that are using unit distance between adjacent categories and square 
distance weights for weighted kappa. Weighted kappa consists of 
considering what the disagreements between observers’ quotations 
contribute partially to agreement if they are not extreme. This 
contribution is quantified by a decreasing weight when quota-
tions diverge on the ordinal scale. When using the square distance 
weighted kappa for RS, weights would be: 1 for perfect agreement, 
0 for maximal disagreement (i0 and i4), 0.75 in the case of disa-
greement between i0 and i2, i1 and i3, or i2 and i4, and 0.44 in 
the case of disagreement between i0 and i3, or i1 and i4. It means 
that two disagreements from i0 and i3, having a total weight of 
0.88, would provide a similar contribution to agreement than one 
perfect agreement weighted 1.00. This demonstrates that, converse 
to unweighted kappa, ICC overestimates agreement level of RS on 
a 5-grade scale, by giving too much weight to major disagreements. 
This criticism holds for recent publications using widely ICC to 
assess agreement level of ordinal scores in inflammatory bowel dis-
ease (see for instance Mosli et al.18 for histological assessment of 
disease severity in ulcerative colitis).
The kappa estimates for RS evaluation relative to <i2 versus 
≥i2 were 0.83 in the Kennedy et al. study16 and 0.47 in our study. 
This large difference could be the consequence of colonoscopy 
sampling. Indeed, in the Kennedy et al. study,16 only seven colonos-
copies (16%) were rated i2 and 15 (35%) i3 or i4 by the original 
endoscopist, compared with 19 (49%) and 4 (10%) in our study, 
Table 2: Characteristics of the 39 patients.
Variable n (%) or median  
(interquartile range)
Age (years) 32 (28–38)
Male gender 14 (36)
Smokers 11 (28)
Time elapsed since diagnosis of CD (months) 41 (17–102)
Previous surgery for CD 9 (23)
Disease location (n = 38)
 small bowel 24 (63)
 small bowel + colon 13 (34)
 colon 1 (3)
Disease behaviour
 non-stenosing, non-penetrating 0 (0)
 stenosing only 22 (57)
 Penetrating 13 (33)
 NA 4 (10)
Months between surgery and ileocolonoscopy 6.1 (5.9–6.4)
Rutgeerts score (156 assessments, 4 per video)
 i0 24 (15)
 i1 22 (14)
 i2 69 (44)
 i3 15 (10)
 i4 26 (17)
NA, not available.
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respectively. It is likely that agreement would be higher when deal-
ing with numerous grade 3 and 4 colonoscopies than when dealing 
with numerous grade 2 colonoscopies. Differences in RS distribu-
tions in the two samples could explain the variation in kappa esti-
mates. Moreover, as described in the seminal paper from Rutgeerts 
et al. and in a recent review from the International Organisation 
of Inflammatory Bowel Disease (IOIBD), the i2 subscore includes 
various postoperative mild lesions on the anastomosis and/or ter-
minal ileum of great heterogeneity and of intermediate prognostic 
value.19
Data from the present study are of importance when consider-
ing clinical trials that have looked at the efficacy of various drugs 
to prevent CD postoperative recurrence using the i2 threshold.3–11 
Meta-analysis of studies testing placebo, 5-ASA, thiopurines, or anti-
TNF agents in this setting have shown the superiority of biologics 
over all other treatments.20 However, the interobserver variation 
observed in the present study may lead to an erroneous assessment 
with potential therapeutic consequences in at least 13% of the cases. 
When considering only severe postoperative recurrence, defined as a 
RS >i2, this meta-analysis suggests that biologics were more effective 
than immunosuppressants, with a difference not reaching statistical 
significance.20 It should be noted that, for this threshold, the propor-
tion of erroneous therapeutic decisions was only 8% in the present 
series. This proportion was not significantly different from the 13% 
estimated for a RS of ≥i2 or more, probably due to the small number 
of colonoscopies graded i3 or i4 in our sample. In clinical practice, it 
does not mean that therapeutic decisions would be more appropri-
ate when using an i3 threshold instead of an i2 threshold: treating 
only patients with RS >i2 would probably avoid overtreatment but 
may undertreat some patients with a high risk of clinical relapse. 
Development of new tools for assessing CD postoperative recur-
rence in addition to RS, such as magnetic resonance imaging or fae-
cal calprotectin, may help the physician to refine the best therapeutic 
approach in this situation.
One of the strengths of the present study was the experience of 
and the large number of endoscopists who had previously used the 
RS for years in daily practice and clinical trials.11 We acknowledge, 
that despite four-fold assessments, the low number of patients with 
severe endoscopic lesions is a limitation. Furthermore, it has not 
been possible to assess in the same time the quality of the videos, 
especially bowel preparation and recording.
In conclusion, the variability of the RS appears large and the 
reproducibility for lesions i2 or more was only moderate. Thus, 
when solely based on the RS, management of patients with CD 
postoperative recurrence may lead to wrong therapeutic initiations. 
Reasons for the variation in the RS evaluation should be studied in 
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